Ori-TIL-102

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NameOri-TIL-102
Drug Alias Nameautologous TILs therapy (Shanghai Origincell Medical Technology)autologous tumor-infiltrating lymphocytes therapy (Shanghai Origincell Medical Technology)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionImmunostimulantsT lymphocytes stimulants
TargetsUpdating
Therapy Area/IndicationsUterine Cervical Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesOriCell Therapeutics Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesOriCell Therapeutics Co Ltd
Inactive CompaniesN/A
Active IndicationsUterine Cervical Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A